A first-in-class regenerative therapeutic for neurodegenerative diseases, with a primary focus on Parkinson’s Disease (PD) and a secondary focus on Alzheimer’s Disease (AD). This program is built on a robust scientific foundation with a mechanism designed to restore homeostatic GABAergic tone, which is critically depleted in chronic stress and neurodegeneration. Beyond symptomatic relief, compelling preclinical and clinical evidence suggests this candidate has disease-modifying and regenerative potential. This treatment is associated with a slowed rate of hippocampal atrophy, with a subset of patients, particularly APOE ε4 carriers. These results provide the first human evidence of a potential regenerative effect, validating the mechanism and significantly de-risking the development path.